Gentium S.p.A. (Nasdaq:GENT) shares are plunging 27% after the biopharmaceutical company said a safety board had worries about the results of its late-stage trial of a treatment for severe veno-occlusive disease. The firm also received a downgrade by Rodman & Renshaw to “Market Perform” from “Outperform.”

For access to the full article, you must be a registered member - it's FREE.